Please login to the form below

Not currently logged in
Email:
Password:

Clostridium difficile

This page shows the latest Clostridium difficile news and features for those working in and with pharma, biotech and healthcare.

After some big setbacks, Sanofi talks up its R&D portfolio

After some big setbacks, Sanofi talks up its R&D portfolio

a blockbuster but now looking to be a liability as its sales are suspended in the Philippines - and the termination of a Clostridium difficile vaccine.

Latest news

More from news
Approximately 4 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    Nestlé has been granted commercial rights (outside the USA and Canada) to a range of products focusing on Clostridium difficile infections (CDI) including SER 109 and SER 262 as well as ... 32, 000. Seres Therapeutics/ Nestle Health Science.

  • Astellas: Ten years young Astellas: Ten years young

    class of OAB treatments to emerge in over 30 years, the antifungal Mycamine (micafungin) and the anti-infective Dificlir - the first new treatment in 50 years for clostridium difficile or c.

  • Cubist: Meeting the challenge in antibiotics Cubist: Meeting the challenge in antibiotics

    x. Hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP). x. surotomycin. Pneumonia Clostridium difficile-associated diarrhoea (CDAD).

  • Pharma deals during December 2014 Pharma deals during December 2014

    The Optimer acquisition brought to Cubist an approved antibacterial drug for the treatment of Clostridium difficile-associated diarrhoea (CDAD) called DIFICID (fidaxomicin).

  • Pharma deals during July 2013 Pharma deals during July 2013

    Cubist had already developed a relationship with Optimer through their 2011 co-promotion agreement for Dificid (fidaxomicin), for the treatment of Clostridium difficile-associated diarrhoea (CDAD) in adults 18 years of

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics